Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.27 (
AMPK
)
6,299
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Single-nucleotide polymorphisms associated with type 2 diabetes (T2D) have been identified in Jazf1, which is also involved in the oncogenesis of endometrial stromal tumors. To understand how Jazf1 variants confer a risk of tumorigenesis and T2D, we explored the functional roles of
JAZF1
and searched for
JAZF1
target genes in myogenic C2C12 cells. Consistent with an increase of Jazf1 transcripts during myoblast proliferation and their decrease during myogenic differentiation in regenerating skeletal muscle,
JAZF1
overexpression promoted cell proliferation, whereas it retarded myogenic differentiation. Examination of myogenic genes revealed that
JAZF1
overexpression transcriptionally repressed MEF2C and MRF4 and their downstream genes. AMP deaminase1 (AMPD1) was identified as a candidate for
JAZF1
target by gene array analysis. However, promoter assays of Ampd1 demonstrated that mutation of the putative binding site for the TR4/
JAZF1
complex did not alleviate the repressive effects of
JAZF1
on promoter activity. Instead,
JAZF1
-mediated repression of Ampd1 occurred through the MEF2-binding site and E-box within the Ampd1 proximal regulatory elements. Consistently, MEF2C and MRF4 expression enhanced Ampd1 promoter activity. AMPD1 overexpression and
JAZF1
downregulation impaired
AMPK
phosphorylation, while
JAZF1
overexpression also reduced it. Collectively, these results suggest that aberrant
JAZF1
expression contributes to the oncogenesis and T2D pathogenesis.
...
PMID:JAZF1 promotes proliferation of C2C12 cells, but retards their myogenic differentiation through transcriptional repression of MEF2C and MRF4-Implications for the role of Jazf1 variants in oncogenesis and type 2 diabetes. 2610 Nov 56
The role of central
juxtaposed with another zinc finger gene 1
(
JAZF1
) in glucose regulation remains unclear. Here, we activated mediobasal hypothalamus (MBH)
JAZF1
in high-fat diet (HFD)-fed rats by an adenovirus expressing
JAZF1
(Ad-JAZF1). We evaluated the changes in the hypothalamic insulin receptor (InsR)-PI3K-Akt-
AMPK
pathway and hepatic glucose production (HGP). To investigate the impact of MBH Ad-
JAZF1
on HGP, we activated MBH
JAZF1
in the presence or absence of ATP-dependent potassium (K
ATP
) channel inhibition, hepatic branch vagotomy (HVG), or an
AMPK
activator (AICAR). In HFD-fed rats, MBH Ad-
JAZF1
decreased body weight and food intake, and inhibited HGP by increasing hepatic insulin signaling. Under insulin stimulation, MBH Ad-
JAZF1
increased InsR and Akt phosphorylation, and phosphatidylinositol 3, 4, 5-trisphosphate (PIP3) formation; however,
AMPK
phosphorylation was decreased in the hypothalamus. The positive effect of MBH
JAZF1
on hepatic insulin signaling and HGP was prevented by treatment with a K
ATP
channel inhibitor or HVG. The metabolic impact of hypothalamic
JAZF1
was also blocked by MBH AICAR. Ad-
JAZF1
treatment in SH-SY5Y cells resulted in an elevation of InsR and Akt phosphorylation following insulin stimulation. Our findings show that hypothalamic
JAZF1
regulates HGP via the InsR-PI3K-Akt-
AMPK
pathway and K
ATP
channels.
...
PMID:Effect of central JAZF1 on glucose production is regulated by the PI3K-Akt-AMPK pathway. 3227 31